AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports
AbbVie is reportedly nearing an $11 billion acquisition of biotech firm Apogee Therapeutics to secure an experimental eczema treatment.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
📍 How it ended
Reports indicated that AbbVie was nearing a deal to buy Apogee Therapeutics for approximately $11 billion. The acquisition would have provided AbbVie with an experimental eczema drug.
The story quieted without a definitive conclusion in the coverage.
Epilogue added 6d ago, after coverage quieted.
The brief
AbbVie is approaching a deal to acquire Apogee Therapeutics. The transaction value is reported as nearly $11 billion, with one source specifying the amount as $10.9 billion.
Coverage from Bloomberg, Reuters, Financial Times, MarketWatch, and Seeking Alpha emphasizes that the acquisition would provide AbbVie with an experimental drug designed to treat eczema. Further updates are expected regarding the finalization of the deal and the specific terms of the acquisition.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 23d ago.
Quick answers
What is the estimated value of the deal?
Reports indicate the deal is nearly $11 billion, with Seeking Alpha citing a figure of $10.9 billion.
Why is AbbVie acquiring Apogee Therapeutics?
According to MarketWatch, the acquisition would allow AbbVie to gain an experimental drug for eczema.
Which news outlets have reported on this trend?
The deal has been covered by the Financial Times, Reuters, Bloomberg, MarketWatch, and Seeking Alpha.
Coverage (6)
- AbbVie to Reportedly Buy Apogee Therapeutics in $10.9 Billion Deal marketscreener.com · 25d ago
- AbbVie Approaching $11 Billion Deal for Apogee Therapeutics, Report Says Bloomberg · 25d ago
- AbbVie would gain an experimental eczema drug by buying biotech: report MarketWatch · 25d ago
- AbbVie said to be nearing a $10.9B deal to buy Apogee Therapeutics Seeking Alpha · 25d ago
- AbbVie closes in on nearly $11bn deal for biotech Apogee Therapeutics Financial Times · 25d ago
- AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports Reuters · 25d ago
Topics
Related trends
FDA releases 14 drug rejection letters after 3-month pause
The FDA has resumed the publication of pharmaceutical rejection letters, issuing 14 new Complete Response Letters following a three-month pause.
Which ‘AI scientist’ suits your lab? A guide for the perplexed
Anthropic has launched a dedicated research workbench for oncology and drug discovery, prompting broad analysis of AI integration in scientific laboratories.
The data that led an AI biotech to pick up Novo's Parkinson's stem cell therapy
An AI biotech firm has acquired Novo's Parkinson's stem cell therapy following promising results from the first human trials.
FDA moves to expose hidden foreign drug factories, strengthen domestic production in sweeping rule proposal
The FDA has introduced a proposal to consolidate registration requirements for distributed drug manufacturing networks, aiming to increase supply chain transparency.
'We're paranoid.' As China biotech competition heats up, American drugmakers get more secretive
6 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
'Mitch' protein that could change the future of weight loss and fat burning
Researchers have identified a protein called 'Mitch' that regulates fat storage and energy usage in cells.